{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:57:53Z","timestamp":1785477473023,"version":"3.56.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01702-5","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:52:40Z","timestamp":1785430360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation Science for Effective Risk Management of Medicines: A Call for Global Action"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4542-5099","authenticated-orcid":false,"given":"Meredith Y.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delese Mimi","family":"Darko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex N. O.","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Inoubli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine H.","family":"Morrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanti","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1702_CR1","unstructured":"Council on International Organizations of Medical Sciences (CIOMS). Practical approaches to risk minimisation for medicinal products. Report of CIOMS Working Group IX, 2014. CIOMS. https:\/\/cioms.ch\/working_groups\/risk-minimisation\/."},{"key":"1702_CR2","unstructured":"European Medicines Agency. The Pharmacovigilance Risk Assessment Committee (PRAC) Strategy on Measuring the Impact of Pharmacovigilance Activities (Rev 1 2017, Rev 2 2022).https:\/\/www.ema.europa.eu\/system\/files\/documents\/other\/prac_strategy_measuring_impact_of_phv_activities_rev_2-en.pdf."},{"key":"1702_CR3","unstructured":"Institute of Medicine (US) Roundtable on Evidence-Based Medicine; Olsen LA, Aisner D, McGinnis JM (Eds). The learning healthcare system: workshop summary. Washington (DC): National Academies Press (US); 2007. Institute of Medicine Roundtable on Evidence-Based Medicine.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK53483\/."},{"key":"1702_CR4","doi-asserted-by":"publisher","unstructured":"Aimer O, Salas M, Hammad T, Mouchantaf R, Ilic K, Mehta U, et al. Advances in drug safety-highlights from the 23rd Annual Meeting of the International Society of Pharmacovigilance. https:\/\/doi.org\/10.1007\/s40264-024-01507-4.","DOI":"10.1007\/s40264-024-01507-4"},{"key":"1702_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40264-024-01451-3","volume":"47","author":"P Bahri","year":"2024","unstructured":"Bahri P, Genov G, Arlett P, et al. The STAR compass to guide future pharmacovigilance based on a 10-year review of the strengthened EU system. Drug Saf. 2024;47:941\u201356.","journal-title":"Drug Saf"},{"key":"1702_CR6","unstructured":"World Health Organization (WHO).\u00a0WHO global smart pharmacovigilance strategy. Geneva: WHO; 7 Nov 2025.\u00a0License: CC BY-NC-SA 3.0 IGO.\u00a0https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/b1187a0f-dd39-4f3a-a55b-d698a0b20160\/content."},{"key":"1702_CR7","volume-title":"WHO \u201cSMART\u201d pharmacovigilance strategy","author":"World Health Organization (WHO)","year":"2024","unstructured":"World Health Organization (WHO). WHO \u201cSMART\u201d pharmacovigilance strategy. Geneva: WHO; 2024."},{"key":"1702_CR8","volume-title":"WHO global smart pharmacovigilance strategy: synopsis","author":"World Health Organization (WHO)","year":"2025","unstructured":"World Health Organization (WHO). WHO global smart pharmacovigilance strategy: synopsis. WHO; 2025."},{"key":"1702_CR9","unstructured":"World Health Organization. Global benchmarking tools. https:\/\/www.who.int\/tools\/global-benchmarking-tools"},{"key":"1702_CR10","unstructured":"World Health Organization (WHO). WHO Pharmacovigilance Partners\u2019 Meeting, Meeting Report, 13 October 2024, New Delhi, India (internal WHO document). Available upon request."},{"key":"1702_CR11","unstructured":"European Medicines Agency and Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Module XVI \u2013 Risk minimisation measures (Rev 3). 2021 and 2024. 2021 draft: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-selection-tools-effectiveness-indicators-rev-3_en.pdf and 2024 final version: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-rev-3_en.pdf."},{"key":"1702_CR12","unstructured":"Food and Drug Administration. REMS Assessment: Planning and Reporting Guidance for Industry. Draft Guidance. 2019. https:\/\/www.fda.gov\/media\/119790\/download."},{"key":"1702_CR13","unstructured":"Ministry of Health, Labour and Welfare. Risk Management Plan Guidance (PFSB\/SD notification no. 0411-1, PFSB\/ELD notification no. 0411-2). Pharmaceuticals and Medical Devices Agency. 2012. https:\/\/www.pmda.go.jp\/files\/000153333.pdf."},{"key":"1702_CR14","unstructured":"Health Canada. Submitting Risk Management Plans Guidance Document. (Catalogue No. H164-359\/2025E-PDF, ISBN 978-0-660-75363-8)."},{"key":"1702_CR15","unstructured":"Health Sciences Authority. (2024). Guidance for industry and applicants: Post-marketing vigilance requirements for therapeutic products and cell, tissue and gene therapy products. Health Sciences Authority, Singapore. https:\/\/www.hsa.gov.sg\/other-regulations\/product-safety-monitoring\/risk-management-plan\/ [1, 2]."},{"key":"1702_CR16","unstructured":"Therapeutic Goods Administration. (2019). Risk management plans for medicines and biologicals (Version 3.3). Australian Government Department of Health. https:\/\/www.tga.gov.au\/sites\/default\/files\/risk-management-plans-medicines-and-biologicals.pdf and European Medicines Agency & Therapeutic Goods Administration. (2012). Guideline on good pharmacovigilance practices (GVP) Module XVI - Risk minimisation measures: selection of tools and effectiveness indicators (EMA\/204715\/2012). https:\/\/www.tga.gov.au\/resources\/guidance\/submitting-risk-management-plans-medicines-and-biologicals [1, 2]."},{"issue":"2","key":"1702_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","volume":"89","author":"R Kiguba","year":"2023","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491\u2013509. https:\/\/doi.org\/10.1111\/bcp.15193.","journal-title":"Br J Clin Pharmacol"},{"key":"1702_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241300006","author":"O Menang","year":"2025","unstructured":"Menang O, van Eeuwijk P, Maigetter K, Stergachis A, Burri C. Pharmacovigilance processes in low- and middle-income countries: moving from data collection to data analysis and interpretation. Ther Adv Drug Saf. 2025. https:\/\/doi.org\/10.1177\/20420986241300006.","journal-title":"Ther Adv Drug Saf."},{"issue":"5","key":"1702_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/14740338.2019.1612875","volume":"18","author":"E Artime","year":"2019","unstructured":"Artime E, Qizilbash N, Garrido-Estepa M, et al. Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opin Drug Saf. 2019;18(5):443\u201354. https:\/\/doi.org\/10.1080\/14740338.2019.1612875.","journal-title":"Expert Opin Drug Saf"},{"key":"1702_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01487-5","author":"M M\u00f8lleb\u00e6k","year":"2025","unstructured":"M\u00f8lleb\u00e6k M, Gardarsdottir H, Bikou AG, et al. Challenges in the implementation of EU risk minimisation measures for medicinal products in clinical practice guidelines: mixed methods multi-case study. Drug Saf. 2025. https:\/\/doi.org\/10.1007\/s40264-024-01487-5.","journal-title":"Drug Saf"},{"key":"1702_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3034","author":"RJ Grupstra","year":"2016","unstructured":"Grupstra RJ, Goedecke T, Scheffers J, Strassmann V, Gardarsdottir H. Review of studies evaluating effectiveness of risk minimization measures assessed by the European Medicines Agency between 2016 and 2021. Clin Pharmacol Ther. 2016. https:\/\/doi.org\/10.1002\/cpt.3034.","journal-title":"Clin Pharmacol Ther"},{"key":"1702_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/pds.4434","volume":"27","author":"P Vora","year":"2018","unstructured":"Vora P, Artime E, Soriano-Gabarr\u00f3 M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic register of post-authorization studies. Pharmacoepidemiol Drug Saf. 2018;27:695\u2013706. https:\/\/doi.org\/10.1002\/pds.4434.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1702_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40290-020-00361-w","volume":"34","author":"E Artime","year":"2020","unstructured":"Artime E, Qizilbash N, Herruzo R, et al. Risk minimisation evaluation with process indicators and behavioural or health outcomes in Europe: systematic review. Pharm Med. 2020;34:387\u2013400. https:\/\/doi.org\/10.1007\/s40290-020-00361-w.","journal-title":"Pharm Med"},{"key":"1702_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s4026401401970","author":"MY Smith","year":"2014","unstructured":"Smith MY, Morrato E. Advancing the field of pharmaceutical risk minimization through application of implementation science best practices. Drug Saf. 2014. https:\/\/doi.org\/10.1007\/s4026401401970.","journal-title":"Drug Saf"},{"issue":"1","key":"1702_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40359-015-0089-9.PMID:26376626;PMCID:PMC4573926","volume":"3","author":"MS Bauer","year":"2015","unstructured":"Bauer MS, Damschroder L, Hagedorn H, Smith J, Kilbourne AM. An introduction to implementation science for the non-specialist. BMC Psychol. 2015;3(1):32. https:\/\/doi.org\/10.1186\/s40359-015-0089-9.PMID:26376626;PMCID:PMC4573926.","journal-title":"BMC Psychol."},{"key":"1702_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-020-01033-z","volume":"44","author":"R Mouchantaf","year":"2021","unstructured":"Mouchantaf R, Auth D, Moride Y, et al. Risk management for the 21st century: current status and future needs. Drug Saf. 2021;44:409\u201319. https:\/\/doi.org\/10.1007\/s40264-020-01033-z.","journal-title":"Drug Saf"},{"key":"1702_CR27","first-page":"5","volume-title":"Implementation research in health: a practical guide","author":"DH Peters","year":"2013","unstructured":"Peters DH, Tran NT, Adam T. Implementation research in health: a practical guide. Alliance for Health Policy and Systems Research, World Health Organization; 2013. p. 5."},{"key":"1702_CR28","unstructured":"World Health Organization. Implementation research resources. https:\/\/implementationscience-gacd.org\/who-ir\/."},{"key":"1702_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00905-8","author":"A Russell","year":"2020","unstructured":"Russell A, Morrato EH, Lovett R, Smith M. Quality of reporting on the evaluation of risk minimization programs: a systematic review. Drug Saf. 2020. https:\/\/doi.org\/10.1007\/s40264-020-00905-8.","journal-title":"Drug Saf"},{"key":"1702_CR30","unstructured":"Food and Drug Administration. REMS Logic Model: A Framework to Link Program Design With Assessment Guidance for Industry -Draft Guidance, 2024. https:\/\/www.fda.gov\/media\/178291\/download."},{"issue":"7","key":"1702_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40264-025-01533-w","volume":"48","author":"MY Smith","year":"2025","unstructured":"Smith MY, Davis R, Bahri P, Saragoussi D, Nguyen V, Toyserkani GA, et al. Using mixed methods to evaluate risk minimisation programs in Europe and the USA: an innovative blueprint. Drug Saf. 2025;48(7):821\u201338.","journal-title":"Drug Saf"},{"issue":"7","key":"1702_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40264-025-01542-9","volume":"48","author":"GA Toyserkani","year":"2025","unstructured":"Toyserkani GA, Robottom SB, Morrato EH. REMS logic model: a pragmatic framework for incorporating drug safety into clinical practice. Drug Saf. 2025;48(7):715\u20138. https:\/\/doi.org\/10.1007\/s40264-025-01542-9.","journal-title":"Drug Saf"},{"key":"1702_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06808-3","volume":"21","author":"L Huynh","year":"2014","unstructured":"Huynh L, Toyserkani GA, Morrato EH. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018). BMC Health Serv Res. 2014;21:779.","journal-title":"BMC Health Serv Res"},{"key":"1702_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fpubh.2020.00043","volume":"8","author":"GA Toyserkani","year":"2020","unstructured":"Toyserkani GA, Huynh L, Morrato EH. Adaptation for regulatory application: a content analysis of FDA risk evaluation and mitigation strategies assessment plans (2014\u20132018) using RE-AIM. Front Public Health. 2020;8:43. https:\/\/doi.org\/10.3389\/fpubh.2020.00043.","journal-title":"Front Public Health"},{"key":"1702_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01417-5","author":"MY Smith","year":"2024","unstructured":"Smith MY, Morrato EH, Mora N, et al. The reporting recommendations intended for pharmaceutical risk minimization evaluation studies: standards for reporting of implementation studies extension (RIMES-SE). Drug Saf. 2024. https:\/\/doi.org\/10.1007\/s40264-024-01417-5.","journal-title":"Drug Saf"},{"issue":"356","key":"1702_CR36","doi-asserted-by":"publisher","first-page":"i6795","DOI":"10.1136\/bmj.i6795","volume":"6","author":"H Pinnock","year":"2017","unstructured":"Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for Reporting Implementation Studies (StaRI) Statement. BMJ. 2017;6(356):i6795. https:\/\/doi.org\/10.1136\/bmj.i6795.","journal-title":"BMJ"},{"key":"1702_CR37","unstructured":"European Medicines Agency and Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Module XVI \u2013 Risk minimisation measures (Rev 3) Addendum II Methods for evaluating the effectiveness of risk minimisation measures, Section XVI. App.II. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-ii-methods-evaluating-effectiveness-risk-minimisation-measures_en.pdf."},{"key":"1702_CR38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/pds.3859","volume":"24","author":"C Radawski","year":"2015","unstructured":"Radawski C, Morrato E, Hornbuckle K, Bahri P, Smith M, Juhaeri J, et al. Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. Pharmacoepidemiol Drug Saf. 2015;24:1233\u201340.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1702_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40264-017-0619-x","volume":"41","author":"MY Smith","year":"2018","unstructured":"Smith MY, Russell A, Bahri P, Mol PGM, Frise S, Freeman E, et al. The RIMES Statement: a checklist to assess the quality of studies evaluating risk minimization programs for medicinal products. Drug Saf. 2018;41:389\u2013401.","journal-title":"Drug Saf"},{"issue":"S2","key":"1702_CR40","first-page":"23","volume":"27","author":"P Bahri","year":"2018","unstructured":"Bahri P, Smith M, Leufkens HGM, Morrato EH. Implementation science: the Art Nouveau of pharmacoepidemiology for improving risk mitigation in health care. Pharmacoepidemiol Drug Saf. 2018;27(S2):23.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1702_CR41","unstructured":"23rd Annual Meeting of the International Society of Pharmacovigilance. Montreal. Conference Program: Mouchantaf R, Bahri P, Morrato E, Moride Y, Delumeau J-C, Stammschulte T. Practical concepts in risk minimization design and evaluation. Pre-conference course, 2 Oct 2024.; Perrott M, Delumeau J-C, Rodriguez L, Massouh R, Bahri P: Digital tools in pharmacovigilance and how they can be improved. Session 9 (Risk management), 3 Oct 2025."},{"key":"1702_CR42","unstructured":"24th Annual Meeting of the International Society of Pharmacovigilance. Cairo; Drug Saf. 2025; 48: 1433-1660: Albabtain A, W AlGhannam, M Aljabreen, N Alabdulrahman, F Alanazi, N Alageel, A Alshayji, N Aljaser, F Alharbi. Phased integration of additional risk minimization measures (aRMMs) into hospital information systems in Saudi Arabia: a national safety initiative. Abstract 179.; Bahri P. Applying mixed methods for tailoring risk communication and minimisation materials to target populations: practical advice for a robust formative approach. Abstract 123.; Morrato E, Campagna E, LaCivita C. Toyserkani G. Risk Evaluation and Risk Mitigation Strategies with elements to ensure safe use: a longitudinal analysis of REMS modifications (2008-2022). Abstract 281."},{"issue":"1","key":"1702_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/XEB.0000000000000416","volume":"23","author":"SN Silva","year":"2025","unstructured":"Silva SN, Ribeiro LR, Borges dos Santos K, Cota G. Promoting safe and appropriate use of miltefosine to treat tegumentary leishmaniasis in Brazil: a best practice implementation project. JBI Evid Implement. 2025;23(1):14\u201323. https:\/\/doi.org\/10.1097\/XEB.0000000000000416.","journal-title":"JBI Evid Implement"},{"key":"1702_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/09564624221121","author":"AJ Edwards","year":"2022","unstructured":"Edwards AJ, Pollard R, Mulamba J, Mbabali I, Anok A, et al. Impact of a community health worker intervention on PrEP knowledge and use in Rakai, Uganda: an implementation science, mixed methods evaluation. Int J STD and AIDS. 2022. https:\/\/doi.org\/10.1177\/09564624221121.","journal-title":"Int J STD and AIDS."},{"key":"1702_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s43058-022-00256-8","volume":"3","author":"JE Kurlander","year":"2022","unstructured":"Kurlander JE, Helminski D, Lanham M, et al. Development of a multicomponent implementation strategy to reduce upper gastrointestinal bleeding risk in patients using warfarin and antiplatelet therapy, and protocol for a pragmatic multilevel randomized factorial pilot implementation trial. Implement Sci Commun. 2022;3:8. https:\/\/doi.org\/10.1186\/s43058-022-00256-8.","journal-title":"Implement Sci Commun"},{"key":"1702_CR46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3332\/ecancer.2019.961","volume":"13","author":"C Pucci","year":"2019","unstructured":"Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. E-Cancer Med Sci. 2019;13:961. https:\/\/doi.org\/10.3332\/ecancer.2019.961. (PMID:31537986;PMCID:PMC6753017).","journal-title":"E-Cancer Med Sci."},{"key":"1702_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.824926","author":"JH Yang","year":"2022","unstructured":"Yang JH, et al. Therapeutic Advances in Multiple Sclerosis. Front Neurology. 2022. https:\/\/doi.org\/10.3389\/fneur.2022.824926.","journal-title":"Front Neurology."},{"key":"1702_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-med-041817-125507","volume":"70","author":"SH Orkin","year":"2019","unstructured":"Orkin SH, Bauer DE. Emerging genetic therapy for sickle cell disease. Ann Rev Med. 2019;70:25\u2013271. https:\/\/doi.org\/10.1146\/annurev-med-041817-125507.","journal-title":"Ann Rev Med."},{"issue":"10","key":"1702_CR49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/jgh3.12829","volume":"6","author":"V Sharma","year":"2022","unstructured":"Sharma V, Kedia S, Ahuja V. Personalized medicine to implementation science: thiopurines set for the leap. JGH Open. 2022;6(10):651\u20137. https:\/\/doi.org\/10.1002\/jgh3.12829. (PMID:36262539;PMCID:PMC9575323).","journal-title":"JGH Open."},{"issue":"6","key":"1702_CR50","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","volume":"184","author":"MS Gebre","year":"2021","unstructured":"Gebre MS, et al. Novel approaches for vaccine development. Cell. 2021;184(6):1589\u2013603.","journal-title":"Cell"},{"key":"1702_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081306","volume":"10","author":"LNH Md Khairi","year":"2022","unstructured":"Md Khairi LNH, Fahrni ML, Lazzarino AI. The race for global equitable access to COVID-19 vaccines. Vaccines. 2022;10:1306. https:\/\/doi.org\/10.3390\/vaccines10081306.","journal-title":"Vaccines"},{"issue":"11","key":"1702_CR52","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1093\/cid\/ciaa622","volume":"71","author":"S Parks Taylor","year":"2020","unstructured":"Parks Taylor S, Kowalkowski MA, Beidas R. Where is the implementation science? An opportunity to apply principles during the COVID-19 pandemic. Clin Infect Dis. 2020;71(11):2993\u20135.","journal-title":"Clin Infect Dis"},{"key":"1702_CR53","volume-title":"Diffusion of innovations","author":"EM Rogers","year":"2002","unstructured":"Rogers EM. Diffusion of innovations. New York: The Free Press; 2002."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01702-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:03:27Z","timestamp":1785474207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01702-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":53,"alternative-id":["1702"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01702-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conception and drafting: MYS and PB; overall global perspective: SP; all authors contributed to the manuscript and agreed with the final version for publication.","order":1,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PB, DMD, ANOD, AI, CP and SP have no conflicts of interest to report. MYS is a shareholder in Amgen, Johnson and Johnson and Eli Lilly and has served as a consultant for the Drug Information Association. EM has served as a consultant for Eli Lilly, Ipsen, and Reata Pharmaceuticals and for the following healthcare organizations and insurers: Health Care Service Corporation, Inc., i2o, Humana, Inc., Molina Healthcare, Inc., Syneos Health and United Healthcare Services. PB and ANOD are Editorial Board members of\n                      Drug Safety\n                      . PB and ANOD were not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as there was no recruitment of human subjects.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}